Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Technology Co., Ltd., particularly its high PE ratio compared to industry averages [1][2] - As of July 16, Canan's closing price was 22.24 yuan, with a rolling PE ratio of 76.09 times, significantly higher than the industry average of 51.87 times and the median of 37.48 times [1][2] - The company has a total market capitalization of 2.719 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - In terms of capital flow, Canan experienced a net outflow of 1.283 million yuan on July 16, with a total outflow of 3.9893 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for Q1 2025 show that Canan achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

7月7日，采纳股份今日收盘21.63元，上涨1.98%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到74.01倍，创63天以来新低，总市值26.44亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.42倍，行业中值37.44倍，采纳股份排 名第99位。 股东方面，截至2025年6月30日，采纳股份股东户数7494户，较上次减少177户，户均持股市值35.28万 元，户均持股数量2.76万股。 采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙头 企业。 最新一期业绩显示，2025年一季报，公司实现营业收入7270.93万元，同比-34.28%；净利润768.02万 元，同比-69.34%，销售毛利率31.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份74.0149.801.4526.44亿行业平均 51.4249.164.50106.60亿行业中值37.4437.842.5151.15亿1九安医疗10.2110.330 ...